

LIMITATIONS OF PROCEDURE

If albumin concentrations are greater than the highest calibrator value, use 1 part sample with 4 parts of one of the following: isotonic saline including 0.05% Tween 20, isotonic saline, or deionized water. Deionized water is an acceptable diluent for diluting high value samples using an analyzer's auto-rerun feature. Re-assay and multiply the result by 5 to compensate for the dilution. If dilution of low value samples is needed, use 1 part sample with 4 parts isotonic saline including 0.05% Tween 20.

PERFORMANCE

Precision

The within-run, between-run, and total precision for the **K-ASSAY**® Microalbumin assay was determined using packaged reagents, human urine samples, and a Roche / Hitachi 917 analyzer in accordance with CLSI EP5-A2.

	Sample 1	Sample 2	Sample 3
N	80	80	80
Mean (mg/dL)	0.311	0.987	27.250
Within Run S.D.	0.019	0.021	0.126
Within Run C.V.	6.007 %	2.168 %	0.463 %
Between Run S.D.	0.012	0.014	0.063
Between Run C.V.	3.840 %	1.411 %	0.229 %
Total S.D.	0.021	0.024	0.166
Total C.V.	6.914 %	2.407 %	0.608 %

Method Comparison / Correlation

Testing was performed on a Roche / Hitachi 917 analyzer using unaltered, natural human urine samples and in accordance with the CLSI EP9-A2 guideline. A comparison of the **K-ASSAY**® Microalbumin and the Roche Tina-Quant Albumin assay was performed with the following results.

Linear Regression:
 $y = 0.9149x + 0.0174$
 $r = 0.9963$
 $n = 91$
 $x =$ Roche Tina-Quant Albumin
 $y =$ **K-ASSAY**® Microalbumin

x min = 0.33 mg/dL y min = 0.38 mg/dL
max = 33.04 mg/dL max = 30.24 mg/dL
mean = 6.918 mg/dL mean = 6.346 mg/dL

Linearity

Testing was performed on a Roche / Hitachi 917 analyzer according to the CLSI EP6-A guideline. A high albumin human urine sample was serially diluted with albumin free human urine to make 12 samples between 0.20 - 30.00 mg/dL and each sample run 5 times with the following results.

First order regression:
 $y = 0.9925x + 0.0308$
 $r = 0.9999$
Standard Error of Regression = 0.075

Assay Range

Testing was performed on a Roche / Hitachi 917 analyzer according to the CLSI EP17-A guideline using native and diluted human urine samples with the following results.

Limit of Blank (LoB) = 0.03 mg/dL
Limit of Detection (LoD) = 0.05 mg/dL
Limit of Quantitation (LoQ) = 0.20 mg/dL

Assay Range: 0.20 – 30.00 mg/dL
(using LoQ as lower limit and highest calibrator as upper limit)

INTERFERENCE

Testing was performed on a Roche / Hitachi 917 analyzer in accordance with the CLSI EP7-A2 guideline with the following results.

Criteria : Recovery within \pm 10% of initial value

Acetone: No interference \leq 350 mg/dL
Ascorbic Acid: No interference \leq 100 mg/dL
Bilirubin: No interference \leq 66 mg/dL
Calcium: No interference \leq 160 mg/dL
Creatinine: No interference \leq 500 mg/dL
Glucose: No interference \leq 2,000 mg/dL
Hemoglobin: No interference \leq 300 mg/dL
Urea: No interference \leq 4,200 mg/dL
Uric Acid: No interference \leq 70 mg/dL
Urobilinogen: No interference \leq 20 mg/dL

Bence-Jones Proteins

Kappa Light Chain: No interference \leq 30 mg/dL
Lambda Light Chain: No interference \leq 30 mg/dL

Administered Diuretics

Furosemide: No interference \leq 400 μ g/mL
Trichlormethiazide: No interference \leq 20 μ g/mL

Analgesic Medications

Acetaminophen: No interference \leq 0.2 mg/mL
Ibuprofen: No interference \leq 2.0 mg/mL

Oral Diabetes Medications

Glibenclamide: No interference \leq 15 μ g/mL
Metformin Hydrochloride: No interference \leq 4.0 μ g/mL

EXPECTED VALUES

The expected value for urinary albumin as per the literature is :
< 2 mg albumin / dL urine
(or < 20 mg albumin / L urine or 0.02 g albumin / L urine).^{7,8}

or
 \leq 30 mg / 24 hours (or \leq 0.03 g / day).⁸

For spot AM samples, the expected values are:
< 0.03 mg albumin / mg creatinine.⁸











Microalbuminuria is typically defined as:
30-300 mg albumin / 24 hours.⁸

Due to population differences, each laboratory should establish its own expected values using this kit.

REFERENCES

1. Harmoinen, A., *et al.*, *Clinica Chimica Acta*. 149:269-274 (1985).
2. Morgensen, C.E., *N. Engl. J. Med.* 310:356-360 (1984).
3. Morgensen, C.E. and Christensen, C.K., *N. Engl. J. Med.* 311: 89-93 (1984).
4. Viberti, G.C., *et al.*, *Lancet*. 1430-1432 (1982).
5. American Diabetes Association, "Standards of Medical Care in Diabetes-2008", *Diabetes Care* 2008 31(Suppl 1):S29-S30.
6. World Health Organization, *Use of Anticoagulants in Diagnostic Laboratory Investigations* (WHO/DIL/LAB/99.1 Rev. 2, 2002), p. 46.
7. Burtis, Carl A., *et al.*, *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 4th Edition* (Elsevier Saunders, 2006), p. 547.
8. Jacobs, David S., *et al.*, *Laboratory Test Handbook, 4th Edition* (Lexi-Comp Inc, 1996), p. 643.

LABELING SYMBOLS

	Lot Number
	Reagent
	Expiration or "Use By" Date
	Catalog Number
	For <i>In Vitro</i> Diagnostic Use
	Temperature Limitation. Store between 2 and 8 degrees C
	Potential Human Biohazard
	Manufacturer
	Consult Package Insert for Instructions for Use
	Authorized Representative in the European Community

EU AUTHORIZED REPRESENTATIVE



Advena Ltd.
Tower Business Centre, 2nd Flr.,
Tower Street, Swatar, BKR 4013 Malta

ORDERING / PRICING / TECHNICAL INFORMATION



KAMIYA BIOMEDICAL COMPANY
12779 Gateway Drive
Seattle, WA 98168 USA
TEL: (206) 575-8068 / (800) 526-4925
FAX: (206) 575-8094